Pharmala Biotech Holdings Revenue

Pharmala Biotech Holdings had revenue of 206.44K CAD in the quarter ending November 30, 2025, with 260.30% growth. This brings the company's revenue in the last twelve months to 754.64K, up 121.87% year-over-year. In the fiscal year ending August 31, 2025, Pharmala Biotech Holdings had annual revenue of 605.50K, down -41.51%.

Revenue (ttm)

754.64K CAD

Revenue Growth

+121.87%

P/S Ratio

14.05

Revenue / Employee

n/a

Employees

n/a

Market Cap

7.59M USD

Revenue Chart

* This company reports financials in CAD.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Aug 31, 2025	605.50K	-429.80K	-41.51%
Aug 31, 2024	1.04M	503.29K	94.60%
Aug 31, 2023	532.00K	453.93K	581.44%
Aug 31, 2022	78.07K	-	-
Aug 31, 2021	-	-	-

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Pharmala Biotech Holdings News

2 days ago - PharmAla Announces Changes to Board of Directors - GlobeNewsWire
5 weeks ago - PharmAla To Supply Østfold Hospital Trust with LaNeo™ MDMA for Clinical Research - GlobeNewsWire
7 weeks ago - PharmAla Issues Audited Year End 2025 and Unaudited Q1 Fiscal 2026 Financial Statements - GlobeNewsWire
2 months ago - PharmAla Biotech Australia Contracts with UK-based CDMO for Manufacture of ALA-002 Drug Substance - GlobeNewsWire
2 months ago - PharmAla Biotech Completes Release Testing on Australian-Made LaNeo Capsules - GlobeNewsWire
3 months ago - PharmAla Files Final Base Shelf Prospectus and Signs Term Sheet with Radium Capital - GlobeNewsWire
4 months ago - PharmAla Launches Nexus Portal for MDMA Prescribers and Therapists - GlobeNewsWire
4 months ago - PharmAla Completes Shipment of LaNeo™ MDMA to Johns Hopkins - GlobeNewsWire

More News